Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter
- 14 November 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (22) , 6329-6330
Abstract
We recently treated a BRAF V600E–mutant metastatic conjunctival melanoma patient with vemurafenib. This 45-year-old male developed metastatic disease 14 months after resection of a primary conjunctival melanoma on the right cornea. On evaluation, he had nodal, subcutaneous, pulmonary, and osseous metastases. Pyrosequencing demonstrated that his melanoma harbored the BRAF V600E mutation. He was initiated on vemurafenib 960 mg twice daily. After 1 month on therapy, he experienced clinical benefit with improvement in pain and subjective tumor regression. However, restaging scans after 2 months of treatment showed a mixed response, predominantly with disease progression (Fig. 1). This included progressive adenopathy in the left axilla and retroperitoneum, as well as an enlarging paraspinal mass, while regression occurred at a single mesenteric mass. Vemurafenib was discontinued and he pursued further systemic therapy options.Keywords
This publication has 5 references indexed in Scilit:
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)Clinical Cancer Research, 2013
- Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal MelanomasClinical Cancer Research, 2013
- Which drug, and when, for patients with BRAF-mutant melanoma?The Lancet Oncology, 2013
- Multiplex Ligation-Dependent Probe Amplification of Conjunctival Melanoma Reveals CommonBRAFV600E Gene Mutation and Gene Copy Number ChangesInvestigative Ophthalmology & Visual Science, 2011
- Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanomaBritish Journal of Ophthalmology, 2010